- 专利标题： ISOLATED INTERLEUKIN-34 POLYPEPTIDE FOR USE IN PREVENTING TRANSPLANT REJECTION AND TREATING AUTOIMMUNE DISEASES
-
申请号： US17371646申请日： 2021-07-09
-
公开(公告)号： US20210401940A1公开(公告)日： 2021-12-30
- 发明人: Carole GUILLONNEAU , Ignacio ANEGON , Séverine BEZIE
- 申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE NANTES
- 申请人地址： FR Paris; FR Nantes
- 专利权人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE),UNIVERSITÉ DE NANTES
- 当前专利权人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE),UNIVERSITÉ DE NANTES
- 当前专利权人地址： FR Paris; FR Nantes
- 优先权： EP14306165.3 20140717,EP15305935.7 20150616
- 主分类号： A61K38/20
- IPC分类号： A61K38/20 ; A61K45/06 ; A61K31/436 ; G01N33/564 ; G01N33/68
摘要：
The invention relates to an isolated interleukin-34 (IL-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies, comprising a step of determining the expression level of IL-34 in a biological sample obtained from said patient, wherein the presence of IL-34 is indicative of a reduced risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies.
公开/授权文献
信息查询
IPC分类:
